Literature DB >> 24704114

Level III-IV inferior vena caval thrombectomy without cardiopulmonary bypass: long-term experience with intrapericardial control.

Mukul B Patil1, Jeremy Montez1, Jeffrey Loh-Doyle1, Jie Cai1, Eila C Skinner1, Anne Schuckman1, Duraiyah Thangathurai1, Donald G Skinner1, Siamak Daneshmand2.   

Abstract

PURPOSE: Inferior vena cava tumor thrombectomy requires experienced surgical teams due to complex hemodynamic considerations. The teams often use vascular bypass techniques that introduce additional risk. Inferior vena caval control in the pericardium obviates the need for cardiopulmonary bypass. We reviewed our experience with intrapericardial control during inferior vena caval tumor thrombectomy to evaluate perioperative outcomes and determine factors associated with overall survival.
MATERIALS AND METHODS: We retrospectively reviewed the records of 87 patients who underwent nephrectomy with inferior vena caval tumor thrombectomy using intrapericardial inferior vena caval control from 1978 to 2012. This technique was performed in all 43 and 35 cases of intrahepatic and supradiaphragmatic thrombi, respectively, and in 9 select cases of intra-atrial thrombi. Patient demographics, operative variables and postoperative outcomes were examined. Multivariate regression analysis was used to determine associations between clinical variables and overall survival.
RESULTS: Mortality 30 days perioperatively was 9.2% and the incidence of high grade complications was 19.5%. Median survival was 3.1 and 2.5 years in patients with pT3bN0 and pT3cN0, respectively. Extended regional lymphadenectomy, which was performed in all cases, revealed nodal metastasis in 38%. On multivariate analysis ECOG greater than 2 and pT3c stage were associated with worse survival. Histological grade, perinephric fat invasion and lymph node involvement were not associated with worse survival.
CONCLUSIONS: Intrapericardial control of the inferior vena cava enables a single surgical team to safely perform tumor thrombectomy for intrahepatic and supradiaphragmatic thrombi, eliminating the risk and morbidity related to cardiopulmonary bypass. Although supradiaphragmatic extent and ECOG greater than 2 are associated with worse survival, complete resection with lymphadenectomy can allow for long-term survival in patients with locally advanced disease.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  carcinoma; inferior; kidney; mortality; renal cell; thrombosis; vena cava

Mesh:

Year:  2014        PMID: 24704114     DOI: 10.1016/j.juro.2014.03.112

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Surgical management of renal cell carcinoma with associated tumor thrombus extending into the inferior vena cava: A 10-year single-center experience.

Authors:  Ramazan Topaktaş; Ahmet Ürkmez; Emre Tokuç; Rıdvan Kayar; Hüseyin Kanberoğlu; Metin İshak Öztürk
Journal:  Turk J Urol       Date:  2019-02-04

2.  Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.

Authors:  Hao G Nguyen; Derya Tilki; Marc A Dall'Era; Blythe Durbin-Johnson; Joaquín A Carballido; Thenappan Chandrasekar; Thomas Chromecki; Gaetano Ciancio; Siamak Daneshmand; Paolo Gontero; Javier Gonzalez; Axel Haferkamp; Markus Hohenfellner; William C Huang; Estefania Linares Espinós; Philipp Mandel; Juan I Martinez-Salamanca; Viraj A Master; James M McKiernan; Francesco Montorsi; Giacomo Novara; Sascha Pahernik; Juan Palou; Raj S Pruthi; Oscar Rodriguez-Faba; Paul Russo; Douglas S Scherr; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Daniel Vergho; Eric M Wallen; Evanguelos Xylinas; Richard Zigeuner; John A Libertino; Christopher P Evans
Journal:  J Urol       Date:  2015-03-19       Impact factor: 7.450

Review 3.  Surgical treatment of renal cell carcinoma with inferior vena cava tumor thrombus.

Authors:  Shi-Min Yuan
Journal:  Surg Today       Date:  2022-01-03       Impact factor: 2.540

Review 4.  Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma.

Authors:  Sarah P Psutka; Bradley C Leibovich
Journal:  Ther Adv Urol       Date:  2015-08

5.  Robotic Level III Inferior Vena Cava Tumor Thrombectomy: Initial Series.

Authors:  Inderbir S Gill; Charles Metcalfe; Andre Abreu; Vinay Duddalwar; Sameer Chopra; Mark Cunningham; Duraiyah Thangathurai; Osamu Ukimura; Raj Satkunasivam; Andrew Hung; Rocco Papalia; Monish Aron; Mihir Desai; Michele Gallucci
Journal:  J Urol       Date:  2015-04-06       Impact factor: 7.600

6.  Early occlusion control of the intrapericardial inferior vena cava under femoral-femoral extracorporeal circulation using a technique to prevent pulmonary embolism during nephrectomy for renal cell carcinoma with tumor thrombus: two case reports.

Authors:  Minoru Miyazato; Satoshi Yamashiro; Masato Goya; Hitoshi Inafuku; Akashi Ikehara; Yoshinori Oshiro; Seiichi Saito; Yukio Kuniyoshi
Journal:  BMC Res Notes       Date:  2014-10-01

7.  Supradiaphragmatic Inferior Vena Caval Thrombectomy Without Cardiopulmonary Bypass: A Case Series at a Single Center.

Authors:  Mohammad Soleimani; Reza Mohammadi; Navid Masoumi; Mohammad Reza Safarinejad
Journal:  Nephrourol Mon       Date:  2016-07-31

8.  Removal of the Tumor Thrombus from the Right Atrium without Extracorporeal Circulation: Emphasis on the Displacement of the Tumor Apex.

Authors:  D V Shchukin; V N Lesovoy; G G Khareba; A I Harahatyi; A V Maltsev; M M Polyakov; R V Stetsyshyn; M P Kopytsya; P V Mozzhakov; O O Makovozov
Journal:  Adv Urol       Date:  2020-06-18

9.  Modified technique of cavoatrial tumor thrombectomy without cardiopulmonary by-pass and hypothermic circulatory arrest: a preliminary report.

Authors:  Robert Sobczyński; Tomasz Golabek; Mikolaj Przydacz; Tomasz Wiatr; Jakub Bukowczan; Jerzy Sadowski; Piotr Chłosta
Journal:  Cent European J Urol       Date:  2015-08-21

10.  AUTHOR'S REPLY.

Authors:  Piotr L Chlosta; Tomasz Golabek
Journal:  Cent European J Urol       Date:  2015-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.